1. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR 1981; 136(5): 859-61.
2. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74(2): 243-8.
3. Porter GA. Contrast-associated nephropathy. Am J Cardiol 1989; 64(9): 22E-2E.
4. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH,
Best PJ, et al. Incidence and prognostic importance of acut renal failure after percutaneous intervention. Circulation2002; 105(19): 2259-64.
5. Katzberg RW. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, andnephrotoxicity. Radiology 1997; 204(2): 297-312.
6. Hill JA, Lambert CR, Pepine CJ. Radiographic contrast agents. In: Pepine CJ, Hill JA, Lambert CR. Diagnostic and Therapeutic Cardiac Catheterization. (2nd Ed) Baltimore, Williams & Wilkins, 1994; 192-235.
7. Salem DN, Findlay SR, Isner JM, Konstam MA, Cohen PF. Comparasion ofhistamine release effects of ionic and nonionic radiographic contrast media. Am J Med 1986; 80(3): 382-4.
8. Schwab S, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, Skelton TN, et al. Contrast nephrotoxicity: A randomized study of the nephrotoxicity of ionic versus nonionic contrast following cardiac catheterization. N EnglJMed 1989; 320(3): 149-53.
9. Davidson CJ, Mark DB, Pieper KS, Kisslo KB, Hlatky MA, Gabriel DA, et al. Thrombotic and cardiovascular complications related to nonionic contrast media during cardiac catheterization: analysis of8517 patients. Am JCardiol 1990; 65(22): 1481-4.
10. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality. Am J Med 1997; 103(5): 368-75.
11. Tippins RB, Torres WE, Baumgartner BR, Baumgarten DA. Are screening serum creatinine levels necessary prior to outpatient CT examinations? Radiology 2000; 216(2): 481-4.
12. Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2): S17-31.
13. Moore RD, Steinberg EP, Powe NR, Brinker JA, Fishman EK, Graziano S, et al. Nephrotoxicity ofhigh-osmolarity vs low-osmolarity contrast media: randomizedclinicaltrial. Radiology 1992; 182(3):
649-55.
14. Barrett BJ, Parfrey PS, Vavasour HM, McDonald J, Kent G, Hefferton D, et al. Contrast nephropathy in patients with impaired renal function: high versus low osmolarmedia. Kidney Int 1992; 41(5): 1274-9.
15. Parfrey PS, Griffiths SM, Barret BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled studt. N Engl J Med 1989; 320(3):143-9.
16. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994; 45(1) :259-65.
17. Vaamonde CA, Bier RT, Rapendick R, Alpert H, Gouvea W, Owens B, et al. Acute and chronic renal
S.D.Ü. Tıp Pak.
Derg
. 2005:12(3)/ 62-68
68
Acar, Kontrast madde nefropatisi
effects of radiocontrast in diabetic rats. Invest Radiol 1989; 24(3): 206-18.
18. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomizedtrial. Kidney Int 1995; 47(1): 254-61.
19. Barrett BJ, Carlisle EJ. Meta analysis of the relative nephrotoxicity ofhigh and low-osmolarity iodinated contrastmedia. Radiology 1993; 188(1): 171-8.
20. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomizedclinicaltrial. EurRadiol 1998; 8(1): 144¬7.
21. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348(6): 491-9.
22. Vliestra RE, Nunn CM, Narvarte J, Browne KF. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J 1996; 132(5): 1049-50.
23. Mason RA, Arbeit LA, Giron F. Renal dysfunction afterarteriography. JAMA 1985; 253(7): 1001-4.
24. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40(2): 298-303.
25. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86(6): 649-52.
26. Cochran ST, Wong WS, Roe DJ. Predicting angiography induced acute renal function impairment: clinical riskmodel. Am J Roentgenol 1983; 141(5): 1027-33.
27. Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. InvestRadiol 1999; 34(11): 685-91.
28. Deray G, Martinez F, Cacoub P, Baumelou B, Baumelou A, Jacobs C. A role of adenosine, calcium and ischemia in radiocontrast media induced intrarenal vasoconstriction. AmJNephrol 1990; 10(4): 316-22.
29. Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M. Radiocontrast induced endothelin release in vivo and in vitro. J Am Soc Nephrol 1992; 3(1): 58¬65.
30. Agmon Y, Dinour D, Brezis M. Disparate effects of adenosine A-1 and A-2 receptor agonists on intrarenal blood flow. Am J Physiol 1993; 265(6): F802-6.
31. Arend LJ, Bakris GL, Burnett JC Jr. Role of intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 1987; 110(4): 406-11.
32. Bakris GL, Burnett JC Jr. A role of calcium in radiocontrast-induced reduction in renal hemodynamics. Kidney Int 1985; 27(2): 465-8.
33. Smith MW, Ambudkar IS, Phelps PC, Rogec AL,
Trump BF. MgCh-induced changes in cytosolic Ca2+ of cultured rabbit renal tubular cells. Biochim Biophys Acta 1987; 931(2):130-42.
34. Brezis M, Heyman SN, Dinour D, Epstein FH, Rosen S. Role of nitric oxide in renal medullary oxygenation: studies in isolated and intact rat kidney. J Clin Invest 1991; 88(2): 390-5.
35. Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994; 94(3): 1069-75.
36. Jabs K, Zeidel ML, Silva P. Prostaglandin E2 inhibits Na-K ATPase activity in the inner medullary collecting duct. Am J Physiol 1989; 257(3): F424-30.
37. Lear S, Silvia P, Kelly VE, Epstein FH. Prostaglandin inhibits oxygen consumption in rabbit medullary thick ascending limb. Am J Physiol 1990; 258(5): F1372-
8.
38. Brezis M, Agmon Y, Epstein FH. Determinants of intrarenal oxygenation I. Effects of diuretics. Am J Physiol 1994; 267: F1059-62.
39. Liss P, Nygren A, Olsson U, Ulfendahl HR, Erikson U. Effects of contrast media and mannitol on renal blood flow and red cell aggregation in the rat kidney. KidneyInt 1996; 49(5): 1268-75.
40. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997; 29(3):465-77.
41. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents-a new use for an old drug. N Engl J Med 2000; 343(3):
210-2.
42. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Contrast-media associated nephrotoxicity. Semin Nephrol 1997; 17(1): 15-26.
43. Postlethwaite AE, Kelley WN. Uricosuric effects of radiocontrast agents: study in man of four used preparations. Ann Intern Med 1971; 74(6): 845-52.
44. Berns AS. Nephrotoxicity of contrast media. Kidney Int 1989; 36(4): 730-40.
45. Venkatesan J, Henrich WL. Atheroembolic renal disease. In: Current Therapy in Nephrology and Hypertension. (4th Ed) St. Louis, Mosby, 1998; 274¬9.
46. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast-media associated nephrotoxicity and atheroembolism: a critical review. Am J Kidney Dis 1994; 24(4): 713-27.
Thank you for copying data from http://www.arastirmax.com